Laboratorios (ROVI) | Stock Overview & Key Data
Laboratorios Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €94.80 on May 27, 2024
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Financial Highlights
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2024
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Laboratorios
ROVI
|
4.34B Large-cap | -4.70% | 3.25% | 11.63% | 25.93% | 28.02% | 58.55% | 101.84% | 68.26% | 449.09% | 1,459.62% | 743.04% |
|
Almirall S.A
ALM
|
2.76B Large-cap | -0.47% | 11.78% | -0.16% | 0.79% | -1.40% | 31.68% | 36.63% | -2.60% | -9.40% | 65.19% | -15.31% |
|
Faes Farma S.A
FAE
|
1.51B Large-cap | -2.24% | 6.90% | -6.07% | 6.90% | -8.05% | 15.38% | 50.00% | 38.33% | 75.18% | 77.12% | -48.94% |
|
Laboratorio Reig
RJF
|
220.63M Mid-cap | -1.48% | 5.12% | -1.11% | -10.10% | -0.37% | -8.56% | 3.89% | -52.74% | -22.61% | -61.19% | -89.23% |
| 49.24M Small-cap | 37.20% | 27.36% | 54.11% | 60.71% | 37.76% | 122.04% | 125.00% | 9,542.86% | 743.75% | 743.75% | 743.75% | |
|
Grifols, S.A
GRF
|
6.09B Large-cap | -7.25% | 1.24% | -18.49% | -20.87% | -20.02% | 5.17% | -3.97% | -60.31% | -52.89% | 33.98% | 244.23% |
Ownership & Short Interest
Calculate Your Laboratorios Investment Returns
Long-Term Investment Performance Analysis
Laboratorios stock price in Jul 2016 was €13.62, A €1,000.00 lump sum investment in Laboratorios made 9 years ago would be worth approximately €5,954.48 today, representing a exceptional return of 495.45%. This translates to an annualized return (CAGR) of 20.04%.
9 Years 9 Months Investment Scenario (Jul 2016 - Apr 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ROVI's 52-week high and low?
- In the last 52 weeks, Laboratorios reached a high of €86.70 (on April 21, 2026) and a low of €50.05 (on May 7, 2025).
- What is the market cap and P/E ratio for ROVI?
- Curious about Laboratorios's size and valuation? Its market capitalization stands at 4.34B. When it comes to valuation, the P/E ratio (trailing twelve months) is 36.12, and the forward P/E (looking ahead) is 19.85.
- Does ROVI pay dividends? If so, what's the yield?
- Yes, Laboratorios is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.69%, and the company has paid an average of €1.11 per share annually over the past 3 years.
- Who are Laboratorios's main competitors or similar companies to consider before investing?
When looking at Laboratorios, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Almirall S.A
ALM2.76B Healthcare Drug Manufacturers - Specialty & Generic 31.68% 36.63% Faes Farma S.A
FAE1.51B Healthcare Drug Manufacturers - Specialty & Generic 15.38% 50.00% Laboratorio Reig
RJF220.63M Healthcare Drug Manufacturers - Specialty & Generic -8.56% 3.89% Labiana Health S.A
LAB49.24M Healthcare Drug Manufacturers - Specialty & Generic 122.04% 125.00% Grifols, S.A
GRF6.09B Healthcare Drug Manufacturers - General 5.17% -3.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Laboratorios Farmaceuticos Rovi S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Laboratorios's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 22.33%, the Debt to Equity ratio from the most recent quarter is 18.04, and its Gross Profit Margin stands at 70.23%.
- What is the recent revenue and earnings growth for ROVI?
- Looking at Laboratorios's growth, its revenue over the trailing twelve months (TTM) was €743M. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.70%, and quarterly earnings saw a YoY growth of 82.50%.
- How much of ROVI stock is held by insiders and institutions?
- Wondering who owns Laboratorios stock? Company insiders (like executives and directors) hold about 68.03% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 19.15%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.